Skip to main content
Fig. 8 | Journal of Hematology & Oncology

Fig. 8

From: A novel tRNA-derived fragment AS-tDR-007333 promotes the malignancy of NSCLC via the HSPB1/MED29 and ELK4/MED29 axes

Fig. 8

Targeting AS-tDR-007333 with inhibitor diminished NSCLC tumor growth in vivo. A Schematic experimental overview of the in vivo study. B Representative bioluminescence images of the xenograft tumors in mice after injecting with inhibitor, or inhibitor-NC, respectively. C The mean tumor volumes of AS-tDR-007333-inhibitor group were significantly smaller than that of NC group. D The mean tumor weight of the inhibitor group was lower than that of NC group. E Representative images of the xenograft tumors isolated from the three indicated groups. F–I qRT-PCR analysis showed that AS-tDR-007333-inhibitor suppressed the expression of AS-tDR-007333, MED29, ELK4, and HSPB1 in xenograft tumor tissues. J Representative images of IHC staining, indicating that AS-tDR-007333-inhibitor repressed expression levels of Ki-67 and MED29 proteins in xenograft tumors. *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

Back to article page